vs
Side-by-side financial comparison of FIRST HORIZON CORP (FHN) and Hologic (HOLX). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $888.0M, roughly 1.2× FIRST HORIZON CORP). FIRST HORIZON CORP runs the higher net margin — 29.4% vs 17.1%, a 12.3% gap on every dollar of revenue. On growth, FIRST HORIZON CORP posted the faster year-over-year revenue change (21.8% vs 2.5%). FIRST HORIZON CORP produced more free cash flow last quarter ($389.0M vs $215.2M). Over the past eight quarters, FIRST HORIZON CORP's revenue compounded faster (20.0% CAGR vs 1.5%).
First Horizon Corporation, formerly First Tennessee Bank, is a financial services company, founded in 1864, and based in Memphis, Tennessee. Through its banking subsidiary First Horizon Bank, it provides financial services through locations in 12 states across the Southeast, a region in which it is the fourth largest regional bank.
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
FHN vs HOLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $888.0M | $1.0B |
| Net Profit | $261.0M | $179.1M |
| Gross Margin | — | 56.0% |
| Operating Margin | 38.5% | 22.6% |
| Net Margin | 29.4% | 17.1% |
| Revenue YoY | 21.8% | 2.5% |
| Net Profit YoY | 57.2% | -10.9% |
| EPS (diluted) | $0.51 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $888.0M | $1.0B | ||
| Q3 25 | $889.0M | $1.0B | ||
| Q2 25 | $830.0M | $1.0B | ||
| Q1 25 | $812.0M | $1.0B | ||
| Q4 24 | $729.0M | $1.0B | ||
| Q3 24 | $827.0M | $988.0M | ||
| Q2 24 | — | $1.0B | ||
| Q1 24 | $819.0M | $1.0B |
| Q4 25 | $261.0M | $179.1M | ||
| Q3 25 | $262.0M | $187.2M | ||
| Q2 25 | $241.0M | $194.9M | ||
| Q1 25 | $218.0M | $-17.4M | ||
| Q4 24 | $166.0M | $201.0M | ||
| Q3 24 | $218.0M | $178.6M | ||
| Q2 24 | — | $194.5M | ||
| Q1 24 | $192.0M | $169.9M |
| Q4 25 | — | 56.0% | ||
| Q3 25 | — | 55.6% | ||
| Q2 25 | — | 56.3% | ||
| Q1 25 | — | 37.5% | ||
| Q4 24 | — | 56.8% | ||
| Q3 24 | — | 56.4% | ||
| Q2 24 | — | 55.4% | ||
| Q1 24 | — | 53.3% |
| Q4 25 | 38.5% | 22.6% | ||
| Q3 25 | 38.7% | 22.6% | ||
| Q2 25 | 37.2% | 24.9% | ||
| Q1 25 | 35.1% | -0.7% | ||
| Q4 24 | 28.8% | 22.5% | ||
| Q3 24 | 34.0% | 23.3% | ||
| Q2 24 | — | 24.1% | ||
| Q1 24 | 31.0% | 20.7% |
| Q4 25 | 29.4% | 17.1% | ||
| Q3 25 | 29.5% | 17.8% | ||
| Q2 25 | 29.0% | 19.0% | ||
| Q1 25 | 26.8% | -1.7% | ||
| Q4 24 | 22.8% | 19.7% | ||
| Q3 24 | 26.4% | 18.1% | ||
| Q2 24 | — | 19.2% | ||
| Q1 24 | 23.4% | 16.7% |
| Q4 25 | $0.51 | $0.79 | ||
| Q3 25 | $0.50 | $0.84 | ||
| Q2 25 | $0.45 | $0.86 | ||
| Q1 25 | $0.41 | $-0.08 | ||
| Q4 24 | $0.29 | $0.87 | ||
| Q3 24 | $0.40 | $0.75 | ||
| Q2 24 | — | $0.82 | ||
| Q1 24 | $0.33 | $0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $2.4B |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | $8.8B | $5.2B |
| Total Assets | $83.9B | $9.2B |
| Debt / EquityLower = less leverage | — | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.4B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | — | $2.4B | ||
| Q1 24 | — | $2.2B |
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.5B | ||
| Q1 24 | — | $2.6B |
| Q4 25 | $8.8B | $5.2B | ||
| Q3 25 | $8.9B | $5.0B | ||
| Q2 25 | $9.0B | $4.8B | ||
| Q1 25 | $8.7B | $4.6B | ||
| Q4 24 | $8.8B | $4.8B | ||
| Q3 24 | $9.0B | $5.1B | ||
| Q2 24 | — | $5.0B | ||
| Q1 24 | $8.9B | $4.8B |
| Q4 25 | $83.9B | $9.2B | ||
| Q3 25 | $83.2B | $9.0B | ||
| Q2 25 | $82.1B | $8.8B | ||
| Q1 25 | $81.5B | $8.5B | ||
| Q4 24 | $82.2B | $8.7B | ||
| Q3 24 | $82.6B | $9.2B | ||
| Q2 24 | — | $8.9B | ||
| Q1 24 | $81.8B | $8.7B |
| Q4 25 | — | 0.48× | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.53× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 0.51× | ||
| Q1 24 | — | 0.53× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $396.0M | $229.9M |
| Free Cash FlowOCF − Capex | $389.0M | $215.2M |
| FCF MarginFCF / Revenue | 43.8% | 20.5% |
| Capex IntensityCapex / Revenue | 0.8% | 1.4% |
| Cash ConversionOCF / Net Profit | 1.52× | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | $595.0M | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $396.0M | $229.9M | ||
| Q3 25 | $-200.0M | $355.1M | ||
| Q2 25 | $83.0M | $343.3M | ||
| Q1 25 | $349.0M | $169.4M | ||
| Q4 24 | $191.0M | $189.3M | ||
| Q3 24 | $389.0M | $367.0M | ||
| Q2 24 | — | $405.8M | ||
| Q1 24 | $838.0M | $292.4M |
| Q4 25 | $389.0M | $215.2M | ||
| Q3 25 | $-208.0M | $341.4M | ||
| Q2 25 | $74.0M | $330.5M | ||
| Q1 25 | $340.0M | $153.9M | ||
| Q4 24 | $174.0M | $172.5M | ||
| Q3 24 | $383.0M | $350.6M | ||
| Q2 24 | — | $385.3M | ||
| Q1 24 | $828.0M | $279.6M |
| Q4 25 | 43.8% | 20.5% | ||
| Q3 25 | -23.4% | 32.5% | ||
| Q2 25 | 8.9% | 32.3% | ||
| Q1 25 | 41.9% | 15.3% | ||
| Q4 24 | 23.9% | 16.9% | ||
| Q3 24 | 46.3% | 35.5% | ||
| Q2 24 | — | 38.1% | ||
| Q1 24 | 101.1% | 27.5% |
| Q4 25 | 0.8% | 1.4% | ||
| Q3 25 | 0.9% | 1.3% | ||
| Q2 25 | 1.1% | 1.3% | ||
| Q1 25 | 1.1% | 1.5% | ||
| Q4 24 | 2.3% | 1.6% | ||
| Q3 24 | 0.7% | 1.7% | ||
| Q2 24 | — | 2.0% | ||
| Q1 24 | 1.2% | 1.3% |
| Q4 25 | 1.52× | 1.28× | ||
| Q3 25 | -0.76× | 1.90× | ||
| Q2 25 | 0.34× | 1.76× | ||
| Q1 25 | 1.60× | — | ||
| Q4 24 | 1.15× | 0.94× | ||
| Q3 24 | 1.78× | 2.05× | ||
| Q2 24 | — | 2.09× | ||
| Q1 24 | 4.36× | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FHN
| Commercial Consumer And Wealth Segment | $776.0M | 87% |
| Other | $88.0M | 10% |
| Corporate | $24.0M | 3% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
